Molecule News and Research

RSS

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

ExonHit Therapeutics today reported the signing by Allergan, Inc. and Bristol-Myers Squibb Company of a global exclusive license agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323), ExonHit’s lead compound from the most advanced program of its collaboration with Allergan.

4 Mar 2010

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

Vaccine researchers at HZI find c-di-IMP molecule, more effective than known adjuvants

The adjuvants present in vaccines have a bad reputation. For most people, they are only unnecessary compounds within a medicinal product. This is a misunderstanding since adjuvants have a critical impact on the success of a vaccination. In the best case scenario, one single vaccination shot would be now sufficient for conferring life-long protection.

3 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level.

2 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

First-ever international Omega-3 Awareness Day

Omega-3 Awareness Day, the nonprofit is proud to announce its plans for the first-ever international awareness day scheduled on March 3rd, 2010 at the University of California, Irvine. Teams of world-renowned doctors founded by Carol A. Locke, MD are scheduled to speak on the science and health benefits of Omega-3 essential fatty acids from 3:00 p.m. to 6:30 p.m. PST in front of thousands of students at UCI.

2 Mar 2010

Most strains of pandemic H1N1 flu virus resist Tamiflu, say scientists

If the behavior of the seasonal form of the H1N1 influenza virus is any indication, scientists say that chances are good that most strains of the pandemic H1N1 flu virus will become resistant to Tamiflu, the main drug stockpiled for use against it.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

Life Technologies announces early stage results from SMS technology

Life Technologies Corporation today announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

2 Mar 2010

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.

2 Mar 2010

Bruker BioSpin launches new 300 MHz high-resolution NMR spectrometer

Bruker BioSpin announces the new Fourier 300, an innovative, easy-to-use 300 MHz high-resolution spectrometer that brings Fourier transform (FT) Nuclear Magnetic Resonance (NMR) spectroscopy within every chemist’s reach. With its robust Fourier Probe technology, easy software, miniaturized electronics and proven magnets, the Fourier 300 is a complete proton and carbon 1D and 2D FT-NMR system that delivers powerful performance at an attractive price.

1 Mar 2010

Researchers figure out how ATP molecule broken down in cells

Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.

1 Mar 2010

Study on new drug targets for prevention of tissue inflammation after stroke

Researchers at Albany Medical College are releasing results of a study this week that they say will help refocus the search for new drug targets aimed at preventing or reversing the devastating tissue inflammation that results after heart attack and stroke.

1 Mar 2010

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

The natural-occurring biopolymer known as chitosan is being put forward as an effective alternative to growth-promoting antibiotics in the diet of ruminants, according to research carried out by scientists at the Basque technological centre, Neiker-Tecnalia.

1 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Eli Lilly, Covance announce key milestones of their first-year partnership

Senior executives from Eli Lilly and Company and Covance Inc. announced Friday that the first year of their landmark alliance has been a win-win for both companies, enabling Lilly to expedite the flow of innovation within its pipeline in order to provide improved outcomes for individual patients.

27 Feb 2010

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

REGENERX BIOPHARMACEUTICALS, INC. announced today that a university research team has published an article ahead of print in FASEB Journal, a high-impact scientific journal, describing novel biological properties of several Thymosin beta 4 (Tβ4) peptide fragments.

27 Feb 2010

Molecule News and Research

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Vaccine researchers at HZI find c-di-IMP molecule, more effective than known adjuvants

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

ArQule reports net loss of $36,136,000 for 2009

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

First-ever international Omega-3 Awareness Day

Most strains of pandemic H1N1 flu virus resist Tamiflu, say scientists

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

Life Technologies announces early stage results from SMS technology

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Bruker BioSpin launches new 300 MHz high-resolution NMR spectrometer

Researchers figure out how ATP molecule broken down in cells

Study on new drug targets for prevention of tissue inflammation after stroke

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Eli Lilly, Covance announce key milestones of their first-year partnership

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News